All Trials

A Front-Line Window-of-Opportunity Phase 2 Study of Tarlatamab (Bispecific T Cell Engager: DLL3-CD3) in Patients With Extensive-Stage Small-Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with newly diagnosed extensive-stage (metastatic/recurrent) small-cell lung cancer (ECOG 0–2) with measurable disease, including treated/stable asymptomatic brain metastases and select asymptomatic untreated brain metastases without edema. Patients receive first-line tarlatamab IV monotherapy (DLL3×CD3 bispecific T-cell engager redirecting T cells to DLL3-expressing SCLC) on a window-of-opportunity basis, with early progressors at 4 weeks transitioning to standard platinum chemotherapy plus an immune checkpoint inhibitor, and close monitoring for CRS/ICANS.

ClinicalTrials.gov ID: NCT07423585

Protocol EA2234: A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis - STOPGAP II

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1, microsatellite-stable/MMR-proficient gastric or Siewert type 3 GEJ adenocarcinoma with positive peritoneal cytology and/or peritoneal carcinomatosis (no solid organ metastases except ovarian) who have completed 3–6 months of first-line systemic therapy without significant radiologic peritoneal progression and are candidates for diagnostic laparoscopy/IP port placement. Patients are randomized at laparoscopy to continue physician’s-choice standard systemic therapy alone versus adding intraperitoneal plus IV paclitaxel (a microtubule-stabilizing taxane) with systemic 5-FU/leucovorin on a 21-day cycle.

ClinicalTrials.gov ID: NCT07001748

A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial evaluates ABSK112, a small molecule targeting EGFR exon 20 insertion mutations, in patients with locally advanced or metastatic non-small cell lung cancer characterized by these mutations, focusing on its safety, tolerability, and pharmacokinetics. The study involves dose escalation and an expansion cohort, enrolling adults with measurable disease and a life expectancy of at least three months.

ClinicalTrials.gov ID: NCT06225804

A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: The trial involves adult patients with advanced or metastatic solid tumors, including those with non-small cell lung cancer (NSCLC), breast, and colorectal cancer, particularly focusing on NSCLC with EGFR mutations during dose expansion, testing CPO301, an EGFR-targeting antibody-drug conjugate.

ClinicalTrials.gov ID: NCT05948865

A Phase 1/2, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JIN-A02 in Patients With EGFR Mutant Advanced Non-small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: The trial targets patients with advanced NSCLC with EGFR mutations who have progressed after prior EGFR-TKI (including osimertinib) and/or platinum-based chemotherapy, assessing the safety and efficacy of JIN-A02, a fourth-generation EGFR tyrosine kinase inhibitor designed to overcome resistance related to EGFR mutations such as C797S.

ClinicalTrials.gov ID: NCT05394831

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial involves patients with oligoprogressive non-small cell lung cancer who previously received first-line systemic therapies, evaluating the safety of adding the antimicrobial agent vancomycin to precision hypofractionated radiation therapy. Vancomycin, known for inhibiting bacterial cell wall synthesis, is used here to potentially reduce infections and modulate the immune response.

ClinicalTrials.gov ID: NCT03546829

A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glumetinib (SCC244), a Selective MET Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer Harboring MET-alterations

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial assesses the efficacy and safety of Glumetinib, a selective MET kinase inhibitor, in patients with advanced non-small cell lung cancer harboring MET alterations, including those with METex14 skipping mutations or MET amplification, who may have been previously treated with MET inhibitors.

ClinicalTrials.gov ID: NCT04270591

A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial involves adults with unresectable or metastatic advanced solid tumors who have progressed on prior treatments or are candidates for pembrolizumab, combining pembrolizumab, which targets the PD-1 receptor to enhance immune response, with a personalized neoantigen peptide vaccine designed to stimulate an individualized immune attack against tumor-associated proteins.

ClinicalTrials.gov ID: NCT05269381

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial involves patients with advanced or metastatic solid tumors expressing Nectin-4, including urothelial carcinoma, triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer, who have exhausted standard therapy options. It evaluates LY4052031, an antibody-drug conjugate that targets Nectin-4 to deliver a topoisomerase I inhibitor, aiming to assess its safety, tolerability, and efficacy in these patients.

ClinicalTrials.gov ID: NCT06465069

Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial involves patients with locally advanced or metastatic pancreatic, lung, breast, and colorectal cancers who have progressed after standard treatments and exhibit tumor uptake of [68Ga]Ga-NNS309. It evaluates the safety and preliminary activity of the investigational radioligand [177Lu]Lu-NNS309, which targets specific tumor markers, though its exact mechanism of action is undisclosed.

ClinicalTrials.gov ID: NCT06562192